Lifecore Biomedical Inc (LFCR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.24 is considered Overvalued compared with the five-year average of -78.92. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.35 to 6.45 according to relative valuation method. Compared to the current price of 6.99 USD , Lifecore Biomedical Inc By Overvalued By 8.3%.

Relative Value

Fair Zone

4.35-6.45

Current Price：6.99

8.3%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Lifecore Biomedical Inc (LFCR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Lifecore Biomedical Inc (LFCR) has a current Price-to-Book (P/B) ratio of 214.51. Compared to its 3-year average P/B ratio of 50.04, the current P/B ratio is approximately 328.65% higher. Relative to its 5-year average P/B ratio of 30.10, the current P/B ratio is about 612.68% higher. Lifecore Biomedical Inc (LFCR) has a Forward Free Cash Flow (FCF) yield of approximately -4.70%. Compared to its 3-year average FCF yield of -12.60%, the current FCF yield is approximately -62.72% lower. Relative to its 5-year average FCF yield of -12.82%, the current FCF yield is about -63.36% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for LFCR competitors is 1.64, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR.O) exhibits a P/S ratio of 2.24, which is 37.15% above the industry average. Given its robust revenue growth of 25.92%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of LFCR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of LFCR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LFCR currently overvalued or undervalued?

What is Lifecore Biomedical Inc (LFCR) fair value?

LFCR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Lifecore Biomedical Inc (LFCR) is between 4.35 to 6.45 according to relative valuation method.

How does LFCR's valuation metrics compare to the industry average?

The average P/S ratio for LFCR's competitors is 1.64, providing a benchmark for relative valuation. Lifecore Biomedical Inc Corp (LFCR) exhibits a P/S ratio of 2.24, which is 37.15% above the industry average. Given its robust revenue growth of 25.92%, this premium appears sustainable.

What is the current P/B ratio for Lifecore Biomedical Inc (LFCR) as of Mar 04 2026?

As of Mar 04 2026, Lifecore Biomedical Inc (LFCR) has a P/B ratio of 214.51. This indicates that the market values LFCR at 214.51 times its book value.

What is the current FCF Yield for Lifecore Biomedical Inc (LFCR) as of Mar 04 2026?

As of Mar 04 2026, Lifecore Biomedical Inc (LFCR) has a FCF Yield of -4.70%. This means that for every dollar of Lifecore Biomedical Inc's market capitalization, the company generates -4.70 cents in free cash flow.

What is the current Forward P/E ratio for Lifecore Biomedical Inc (LFCR) as of Mar 04 2026?

As of Mar 04 2026, Lifecore Biomedical Inc (LFCR) has a Forward P/E ratio of -9.21. This means the market is willing to pay $-9.21 for every dollar of Lifecore Biomedical Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Lifecore Biomedical Inc (LFCR) as of Mar 04 2026?

As of Mar 04 2026, Lifecore Biomedical Inc (LFCR) has a Forward P/S ratio of 2.24. This means the market is valuing LFCR at $2.24 for every dollar of expected revenue over the next 12 months.

LFCR Valuation